Achieve Life Sciences Inc. (ACHV) Financial Statements (2025 and earlier)

Company Profile

Business Address 22722 29TH DR. SE
SEATTLE, WA 98021
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:34,400,00042,900,00061,300,00066,398,00015,546,00019,919,000
Cash and cash equivalent12,753,0009,544,00014,756,00066,398,00015,546,00019,919,000
Short-term investments21,607,00033,367,00046,557,000   
Other undisclosed cash, cash equivalents, and short-term investments40,000(11,000)(13,000)   
Receivables     111,00083,000
Other undisclosed current assets2,067,0002,629,0001,219,0001,311,0001,325,0001,895,000
Total current assets:36,467,00045,529,00062,519,00067,709,00016,982,00021,897,000
Noncurrent Assets
Operating lease, right-of-use asset119,00020,00035,00051,00066,00080,000
Property, plant and equipment 8,000   13,000 
Intangible assets, net (including goodwill)2,008,0002,064,0002,120,0002,175,0002,231,0002,286,000
Goodwill1,034,0001,034,0001,034,0001,034,0001,034,0001,034,000
Intangible assets, net (excluding goodwill)974,0001,030,0001,086,0001,141,0001,197,0001,252,000
Other undisclosed noncurrent assets31,000304,000117,00094,00079,00074,000
Total noncurrent assets:2,166,0002,388,0002,272,0002,320,0002,389,0002,440,000
TOTAL ASSETS:38,633,00047,917,00064,791,00070,029,00019,371,00024,337,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,550,0004,250,0002,516,0002,274,0003,280,0003,031,000
Accounts payable1,950,0001,011,000550,000373,000618,000638,000
Accrued liabilities3,600,0003,239,0001,966,0001,901,0002,662,0002,393,000
Debt  8,804,00017,141,00016,662,000 
Other undisclosed current liabilities1,132,0002,466,0002,382,0001,158,000871,0001,051,000
Total current liabilities:6,682,0006,716,00013,702,00020,573,00020,813,0004,082,000
Noncurrent Liabilities
Long-term debt and lease obligation9,837,0009,823,0008,804,000  16,195,000
Long-term debt, excluding current maturities9,837,0009,823,0008,804,000  16,195,000
Liabilities, other than long-term debt1,215,000   6,00022,000
Operating lease, liability66,000   6,00022,000
Business combination, contingent consideration, liability1,149,000     
Total noncurrent liabilities:11,052,0009,823,0008,804,000 6,00016,217,000
Total liabilities:17,734,00016,539,00022,506,00020,573,00020,819,00020,299,000
Equity
Equity, attributable to parent20,899,00031,378,00042,285,00049,456,000(1,448,000)4,038,000
Common stock103,000103,000103,000103,00090,00090,000
Additional paid in capital226,343,000224,418,000222,895,000221,594,000164,209,000164,219,000
Accumulated other comprehensive income (loss)31,00075,000(7,000)4,0004,0004,000
Accumulated deficit(205,578,000)(193,218,000)(180,706,000)(172,245,000)(165,751,000)(160,275,000)
Total equity:20,899,00031,378,00042,285,00049,456,000(1,448,000)4,038,000
TOTAL LIABILITIES AND EQUITY:38,633,00047,917,00064,791,00070,029,00019,371,00024,337,000

Income Statement (P&L) (USD)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
Operating expenses(12,248,000)(12,466,000)(8,531,000)(6,039,000)(4,443,000)(6,572,000)
Operating loss:(12,248,000)(12,466,000)(8,531,000)(6,039,000)(4,443,000)(6,572,000)
Nonoperating income (expense)(170,000)(46,000)(30,000)(512,000)(1,090,000)(536,000)
Investment income, nonoperating482,000673,000833,000368,000208,000262,000
Other nonoperating income (expense)(5,000)(8,000)(2,000)(15,000)17,000(17,000)
Interest and debt expense (283,000) (813,000)(787,000)(781,000)
Loss from continuing operations before equity method investments, income taxes:(12,418,000)(12,795,000)(8,561,000)(7,364,000)(6,320,000)(7,889,000)
Other undisclosed income from continuing operations before income taxes 512,000   3,081,000 
Loss from continuing operations:(11,906,000)(12,795,000)(8,561,000)(7,364,000)(3,239,000)(7,889,000)
Other undisclosed net income (loss)(454,000)  870,000(2,237,000) 
Net loss:(12,360,000)(12,795,000)(8,561,000)(6,494,000)(5,476,000)(7,889,000)
Other undisclosed net income attributable to parent  283,000100,000  781,000
Net loss available to common stockholders, diluted:(12,360,000)(12,512,000)(8,461,000)(6,494,000)(5,476,000)(7,108,000)

Comprehensive Income (USD)

3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
Net loss:(12,360,000)(12,795,000)(8,561,000)(6,494,000)(5,476,000)(7,889,000)
Other comprehensive income (loss)(44,000)82,000(11,000)   
Comprehensive loss:(12,404,000)(12,713,000)(8,572,000)(6,494,000)(5,476,000)(7,889,000)
Other undisclosed comprehensive income, net of tax, attributable to parent  283,000100,000   
Comprehensive loss, net of tax, attributable to parent:(12,404,000)(12,430,000)(8,472,000)(6,494,000)(5,476,000)(7,889,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: